Aarti Drugs (Small Cap - Next Multibagger) Share Target 2024, 2025 To 2039
|
Aarti Drugs Limited |
|||
|
Price: ₹452.70 | ||
| 52 Week Low: ₹419.55 52 Week High: ₹635.00 |
|||
| Market Capital: 4,265.95 Crore (Smallcap) | |||
| Healthcare -> Drug Manufacturers—Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Aarti Drugs Share Price Target For 2024
- 1.1.1: Aarti Drugs Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Aarti Drugs Share Price Target For 2025
- 1.2.1: Aarti Drugs Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Aarti Drugs Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Aarti Drugs Brief Company Overview
- 4: Aarti Drugs Financial Performance
- 4.0.1: Is Aarti Drugs A Good Buy For Long Term?
To predict the Aarti Drugs's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Aarti Drugs Share Price Target For 2024
The line chart displays the monthly closing prices of Aarti Drugs with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Aarti Drugs shares in 2024, see the table below.
Aarti Drugs Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 474.75 (+4.87%) | Price Action: Dec 2022 High |
| 2024 Target 2 | 469.75 (+3.76%) | Price Action: 12 Mar 2024 High |
| 2024 Target 1 | 464.9 (+2.69%) | Price Action: 19 Nov 2024 High |
| Current Price | 452.70 | Aarti Drugs's share price as of 26 Dec 2024 |
| Stop Loss 1 | 447.15 (-1.23%) | Price Action: 17 Dec 2024 High |
| Stop Loss 2 | 441.85 (-2.4%) | Price Action: Oct 2022 Low |
| Stop Loss 3 | 437.15 (-3.44%) | Price Action: 27 Mar 2024 Low |
Short-Term Technical Outlook
Current Technical Position: Aarti Drugs is showing mixed momentum signals near key moving averages.
Key Technical Level: The 25-day moving average at ₹449.86 serves as the nearest technical reference point.
Historical Returns: 3-month: -11.79% | 6-month: -10.28% | 1-year: -7.46%
Aarti Drugs Share Price Target For 2025
The line chart displays the monthly closing prices of Aarti Drugs with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Aarti Drugs shares in 2025, see the table below.
Aarti Drugs Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 594.6 (+31.34%) | Price Action: 01 Aug 2023 Low |
| 2025 Target 2 | 588.2 (+29.93%) | Price Action: 03 Sep 2024 High |
| 2025 Target 1 | 582.05 (+28.57%) | Price Action: 29 Aug 2024 Low |
| Current Price | 452.70 | Aarti Drugs's share price as of 26 Dec 2024 |
| Stop Loss 1 | 419.55 (-7.33%) | Price Action: Dec 2024 Low |
| Stop Loss 2 | 414.45 (-8.44%) | Price Action: Aug 2022 Low |
| Stop Loss 3 | 404.7 (-10.61%) | Price Action: Mar 2023 High |
Long-Term Technical Outlook
52-Week Range Analysis: Aarti Drugs is currently trading near its 52-week low of ₹419.55, indicating potential value opportunity.
Long-Term Trend Analysis: The stock is in a bearish long-term trend, trading below key long-term moving averages.
Long-Term Performance: 1-year: -7.46% | 3-year: -16.92% | 5-year: +212.59%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Aarti Drugs Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹452.70 | ||
| 2024 | ₹525.70 | +16.12% | ₹533.59 |
| 2025 | ₹527.46 | +0.33% | ₹588.52 |
| 2026 | ₹542.73 | +2.89% | ₹616.17 |
| 2027 | ₹643.82 | +18.62% | ₹653.48 |
| 2028 | ₹650.45 | +1.02% | ₹660.21 |
| 2029 | ₹626.38 | -3.7% | ₹671.47 |
| 2030 | ₹624.75 | -0.26% | ₹699.12 |
| 2031 | ₹639.28 | +2.32% | ₹726.77 |
| 2032 | ₹754.41 | +18% | ₹765.73 |
| 2033 | ₹758.47 | +0.53% | ₹769.85 |
| 2034 | ₹727.06 | -4.14% | ₹782.06 |
| 2035 | ₹722.04 | -0.69% | ₹809.71 |
| 2036 | ₹735.82 | +1.9% | ₹837.36 |
| 2037 | ₹865.01 | +17.55% | ₹877.99 |
| 2038 | ₹866.49 | +0.17% | ₹879.49 |
| 2039 | ₹795.11 | -8.23% | ₹892.66 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Aarti Drugs Brief Company Overview
Aarti Drugs Limited: A Comprehensive Overview Established in 1984, Aarti Drugs Limited is a renowned manufacturer and marketer of pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations. With a global presence, Aarti Drugs...
caters to a diverse range of therapeutic areas, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antidiabetics, and Alzheimer's treatment. The company's commitment to innovation is evident in its wide product portfolio. Aarti Drugs offers over 200 products, spanning antibiotics, antifungals, antiarthritis, vitamins, and sedatives. Its specialty chemical products include benzene sulphonyl chloride, benzene sulphonic acid, and formamide. Additionally, the company is developing promising products such as Itraconazole, Fluconazole, and Dabigatran. Aarti Drugs' reputation in the industry is built on its emphasis on quality and customer satisfaction. The company's state-of-the-art facilities and stringent regulatory compliance ensure that its products meet the highest standards. Aarti Drugs is known for its reliable supply chain, competitive pricing, and exceptional customer service. Headquartered in Mumbai, India, Aarti Drugs Limited has established a strong global presence with operations in over 50 countries. The company's unwavering commitment to research, development, and exceptional service has made it a trusted partner for healthcare professionals and patients worldwide.Aarti Drugs Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 4,265.95 Crore | Market valuation of Aarti Drugs's shares. |
| Revenue (TTM) | 2,379.6 Crore | Total revenue generated by Aarti Drugs over the past twelve months. |
| Net Income (TTM) | +152.22 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +9.15% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +6.39% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
-6.7% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
-11.61% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
46.18 | Company's total debt divided by total shareholder equity. |
| Total Debt | 590.1 Crore | Sum of Aarti Drugs's current & long-term financial obligations. |
| Total Cash | 29.56 Crore | Total amount of liquid funds available to Aarti Drugs. |
| Beta | 0.82 | Beta is less than 1 indicating that the Aarti Drugs's price is less volatile than the market. |
Is Aarti Drugs A Good Buy For Long Term?
Aarti Drugs, a small-cap stock with a market capitalization of ₹4,265.95 crore, presents a mixed picture for long-term investors. While its ₹2,379.6 crore revenue (TTM) and ₹152.22 crore net profit are noteworthy, a declining profit margin (6.39%) and negative year-on-year earnings growth (-11.61% in Q2 2024-25) raise concerns. The significant debt (₹590.1 crore) against a low cash balance (₹29.56 crore) further adds to the risk. Although past 5-year returns are positive (212.41%), recent performance has been weak (-8.17% YTD, -36.32% over 3 years). Therefore, it's currently a not a good buy for long-term investment. Further analysis is recommended before considering any investment.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
